COPD Exacerbation Modelling Using Unobtrusive Sensors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-05-08

Study Completion Date

2025-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This work is a multicentric prospective cohort study designed to improve chronic obstructive pulmonary disease (COPD) treatment and management. The study involves 150 patients diagnosed with COPD who are at risk of exacerbations. These patients are recruited from three tertiary hospitals in Spain, Germany, and Italy. The study will last 18 months, with a 12-month follow-up duration for each patient. The primary objective of this study is to develop and test Artificial Intelligence (AI)-based models that can predict moderate-to-severe COPD exacerbations early on. This will be done by analyzing daily-life data collected from unobtrusive sensors that monitor patients' psycho-physiological and environmental signals. By accurately predicting exacerbations, the study aims to support clinicians in providing more precise, optimized, and personalized treatment to COPD patients. A secondary objective is to train and test AI-based models to estimate the 12-month dynamics of health-related quality of life (HRQoL) in COPD patients. This will involve analyzing data related to the patients' functional exercise capacity, dyspnea (difficulty breathing), and health-related quality of life, as measured by the Clinical COPD Questionnaire (CCQ) score and the COPD Assessment Test (CAT) score.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

European Non-interventional Study in Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT00722267

Chronic Obstructive Pulmonary Disease (COPD)

COMPLETED

Severe Chronic Obstructive Pulmonary Disease Inhalation Profiles Comparison

NCT02076269

Pulmonary Disease, Chronic Obstructive

COMPLETED PHASE1

Non-contact Proactive Remote Monitoring of COPD Exacerbations

NCT05598983

COPD Exacerbation

RECRUITING

Monitoring Coughs for the Early Detection of Worsening COPD

NCT07212439

Chronic Obstructive Pulmonary Disease (COPD)

RECRUITING

Cough Monitoring in COPD

NCT07098793

Cough COPD COPD Exacerbation

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Obstructive Pulmonary Disease (COPD)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Variations in daily life activity signals detected by unobtrusive sensors

Patients will be equipped with unobtrusive devices for a duration of 12 months. Throughout this period, they will attend scheduled visits every three months following the baseline visit. These assessments will focus on determining the frequency of exacerbations, evaluating exercise capacity, measuring the severity of dyspnea, and assessing health-related quality of life. The data gathered from the sensors embedded in these unobtrusive devices will be instrumental in developing AI-based models. These models aim to accurately predict COPD exacerbations and effectively estimate the progression of the previously mentioned health outcome.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of COPD (FEV1/FVC \< 0.7) for at least a year.
* Participants with moderate-to-very severe COPD (FEV1 ≤ 80% predicted)
* Documented history of ≥ 1 moderate (treated with SABDs and oral corticosteroids ± antibiotics) or severe COPD exacerbation\* within 12 months before enrolment.
* Adults aged 40 or over.
* Able to walk 4 meters independently with or without walking aids.
* Anticipated availability for repeated study visits over 12 months.
* Willingness to use smart sensors.
* Able to read and write in the first language in the respective location.
* Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and the study protocol.

Exclusion Criteria

* Occurrence of any of the following within three months before informed consent: myocardial infarction, hospitalization for unstable angina, stroke, coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI), implantation of a cardiac resynchronization therapy device (CRTD).
* Uncontrolled congestive heart disease (NYHA class \>3).
* Having undergone major lung surgery (e.g., lung transplant)
* Primary respiratory diseases other than COPD.
* Participant who has experienced a major respiratory infection or exacerbation within 2 weeks before screening
* Lung volume reduction within six months before screening.
* Active treatment for cancer or other malignant diseases that in the opinion of the investigator, have an impact on the patient's quality of life such as to prevent adherence to the study.
* Acute psychosis or major psychiatric disorders or continued substance abuse.
* Severe disease that limits survival to 1 year.
* Patients with severe cognitive impairment (MMSE \< 18).
* Substantial limitations in mobility due to factors other than COPD.
* Inability to follow the study procedures (e.g., due to language problems, psychological disorders) or unable to read, understand and fill in a questionnaire.

Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No